- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04523259
Compatibility Problems and Prescribing Pattern of Injectable Drugs at the Hospital
Drug safety is always a national, as well as international, patient safety goal. Administration of injection, especially intravenous infusion, is an extremely complicated and dangerous process, which includes reconstitution, dilution, selection of diluent and volume, verification of concentration of final solution, check for stability, sterility and compatibilities, and the selection of intravenous (IV) set, peripheral or central route, and the rate of infusion. Due to its inherent complexity, errors occur easily during these procedures. Literatures indicated that the incidence of injection administration errors ranged from 13% to 84%, which included errors in dosage, diluents, and volumes; excessive administration rate; and incompatible IV admixture.
In the U.S.A., pharmacists provide comprehensive clinical services. They ensure the appropriateness of every step in the process from prescription and dosage verification, drug reconstitution and dilution, selection of diluents and concentration, to the rate of administration. Even more, they provide the final IV products that are ready to administer to the patients (IV admixture services). Therefore, many common administration errors can be avoided. In Taiwan, nevertheless, pharmacists have limited role in IV services due to our health-care system. There are no studies on the administration pattern of injections. There is still room for improvement in the assurance of injection safety.
To ensure the safety of injection, we not only have to oversee the accuracy of drugs and dosage, but also take the compatibilities among drugs and diluents seriously.
Because diluent is not a mandatory claim data, the National Health Insurance data base cannot provide the related information for drug compatibility epidemiology study. The application for reimbursement of injections is based on total amount used instead of daily usage; it is therefore difficult to find drug incompatibility problems in this data base. Hospital data base analysis, questionnaire survey and chart review are more feasible for such study.
This study will analyze the prescriptions of IV injection in the intensive-care units and pediatric units to determine the prescribing pattern. High risk IV admixtures and Y-site administrations will be explored by questionnaire survey and literature review. Laboratory experiments will be done on some indicator drugs to find the reasons, categories and severities of the compatibilities. A list of incompatible drugs shall be generated for computerized intervention. We hope the results of the study can be used as a reference for guideline, policy and procedure for health care system and government.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- nurses
Exclusion Criteria:
- not nurses
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Drug incompatibility assessed by questionnaire survey
Tidsramme: 6 months
|
IV admixture
|
6 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Taiwan National Taiwan University Hospital, National Taiwan University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 200911016R
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på IV Injection
-
National Taiwan University HospitalUkjentDirekte Coracohumeral Ligament Steroid InjectionTaiwan
-
NYU Langone HealthMallinckrodtTilbaketrukketSystemisk lupus erythematosus (SLE) | Repository Corticotropin Injection
-
Shanghai Zhongshan HospitalHar ikke rekruttert ennåAvansert magekreft | Paclitaxel Polymeric Micelles for Injection | Fruquintinib kapsler
-
Rhaeos, Inc.RekrutteringIV Infiltrasjon | IV EkstravasasjonForente stater
-
Jerome Canady, M.D.Aktiv, ikke rekrutterendeStadium IV lungekreft | Stadium IV blærekreft | Stadium IV Bukspyttkjertelkreft | Tilbakevendende ondartet fast neoplasma | Stage IV brystkreft | Stadium IV nyrecellekreft | Stage IV prostatakreft | Trinn IV tykktarmskreft | Stadium IV endetarmskreft | Stage IV Magekreft | Stadium IV Ikke-småcellet lungekreft | Stadium... og andre forholdForente stater
-
Peter SzmukLuminex Corporation; Outcomes Research ConsortiumFullførtIV kanyleringForente stater
-
Mohamed abdelsalam Gaber elkhoulyHar ikke rekruttert ennå
-
Centre Francois BaclesseRoche Pharma AGFullførtKreft | IV AntikreftterapiFrankrike
-
Maastricht Radiation OncologyAmsterdam UMC, location VUmcFullført
-
Union Hospital, Tongji Medical College, Huazhong...Har ikke rekruttert ennåLungeplateepitelkarsinom stadium IV